A3739-20 SINGLE SHOT EPIDURAL 20G TUOHY
- Manufacturer
- Smiths Medical ASD, Inc. | Kwang Myung Pharm. Co., Ltd. | Aplicare, Inc.
- Effective date
- 2015-02-12
- Label type
- MEDICAL DEVICE
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:32:59
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
Drug Facts
Povidone-iodine
OTC - PURPOSE SECTION
Antiseptic
Antispetic skin preparation
WARNINGS SECTION
Do not use
-if allergic to iodine.
-in the eyes
For external use only.
Ask a doctor before use if injuries are
-deep or puncture wounds
-serious burns
OTC - STOP USE SECTION
Stop use and ask a doctor if
-redness, irritation, swelling or pain persists or increases
-infection occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children
In case of accidental ingestion, seek professional help or consult a poison control center immediately.
INSTRUCTIONS FOR USE SECTION
Apply locally as needed.
OTHER SAFETY INFORMATION
1% titratable iodine latex free for hospital or professional use only
INACTIVE INGREDIENT SECTION
citric acid, disodium phosphate, nonoxynol-9, sodium hydroxide, water
OTC - QUESTIONS SECTION
1 800 760-3236 (Mon to Fri 8:30 AM-5:00 PM EST)
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Package Label Display Panel
DESCRIPTION SECTION
Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride 0.9% (9 mg/mL) in Water for Injection containing no antimicrobial agent or other added substance. The pH is between 4.5 and 7.0. Its chloride and sodium ion concentrates are approximately 0.154 mEq of each per milliliter and its calculated osmolality is 0.308 milliosmols per mL.
Sodium chloride occurs as colorless cubic crystals or white crystalline powder and has a saline taste. Sodium Chloride is freely soluble in water. It is soluble in glycerin and slightly soluble in alcohol. The empirical formula for sodium chloride is NaCl, and the molecular weight is 58.44.
CLINICAL PHARMACOLOGY SECTION
Sodium chloride comprises over 90% of the inorganic constituents of the blood serum. Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl-) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance. The small volume of Fluid and amount of sodium chloride provided by Sodium Chloride Injection, USP, 0.9% when used only as a vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in very small infants.
INDICATIONS & USAGE SECTION
Sodium Chloride Injection is used to flush intravascular catheters or as a sterile, isotonic single dose vehicle, solvent, or diluent for substances to be administered intravenously, intramuscularly or sub-cutaneously and for other extemporaneously prepared single dose sterile solutions according to instructions of the manufacture of the drug to be administered.
WARNINGS SECTION
Sodium Chloride must be used with caution in the presence of congestive heart failure, circulatory insufficiency, kidney dysfunction or hypoproteinemia. Excessive amounts of sodium chloride by any route may cause hypokalemia and acidosis.
Excessive amounts by parental routes may precipitate congestive heart failure and acute pulmonary edema, especially seen in patients with preexisting cardiovascular disease and those receiving corticos-teroids, corticotropin or other drugs that may give rise to sodium retention. For use in newborns, when a Sodium Chloride solution is required for preparation or diluting medications, or in flushing intravenous catheters, only preservative-free Sodium Chloride Injection, USP, 0.9% should be used.
PRECAUTIONS SECTION
Since Sodium Chloride Injection does not contain antimicrobial agents and is intended for single use, any unused amount must be discarded immediately following withdrawal of any portion of the contents of the vial or ampul. Do not open ampul until it is to be used.
Consult the manufactures instructions for choice of vehicle, appropriate dilution or volume for dissolving the drug to be injected, including the route and rate of injection.
PREGNANCY SECTION
Pregnancy Category C: Animal reproductive studies have not been conducted with Sodium Chloride Injection USP 0.9%. It is also not known whether Sodium Chloride Injection USP 0.9% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection USP 0.9% should be given to a pregnant woman only if clearly needed.
ADVERSE REACTIONS SECTION
Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination.
OVERDOSAGE SECTION
When used as a diluent, solvent or intravascular flushing solution, this parental preparation is unlikely to pose a threat of sodium chloride or fluid overload except possible in very small infants. In the event these should occur, reevaluate the patient and institute appropriate corrective measures.
DOSAGE & ADMINISTRATION SECTION
Before Sodium Chloride Injection, USP, 0.9% is used as a vehicle for the administration of a drug, specific references should be checked for any possible incompatibility with sodium chloride. The volume of the preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacture.
Sodium Chloride Injection, USP, 0.9% is also indicated for use in flushing intravenous catheters. Prior to and after administration of the medication, the intravenous catheter should be flushed in its entirety with Sodium Chloride Injection, USP, 0.9%. Use in accord with any warnings or precautions appropriate to the medication being administered. Parental drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
INSTRUCTIONS FOR USE
To open ampuls, using gauze, place thumb and forefinger on color line, break at constriction.
HOW SUPPLIED SECTION
5 mL ampuls packaged in box of 25 each (NDC-65282-1505-1)
10 mL ampuls packaged in box of 25 each (NDC-65282-1510-1)
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Package Label Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Package Label Display Panel
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 52380-0001-1 | ML - Milliliter | 52380-0001 | edd25a2a-aabd-433e-b5a8-ef9471c1b244 | 1 | 2012-07-24 |
| 52380-0001-3 | ML - Milliliter | 52380-0001 | 9f05eb45-3f8e-4fd9-814a-476eb917bf5c | 1 | 2021-11-09 |
| 52380-0001-5 | EA - Each | 52380-0001 | 9755da7f-19a8-4706-8c70-17752ffe4175 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| POVIDONE-IODINE | ACTIVE INGREDIENT | 85H0HZU99M | 2 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| CHLORIDE ION | ACTIVE MOIETY | Q32ZN48698 | 2 | |
| IODINE | ACTIVE MOIETY | 9679TC07X4 | 2 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| NONOXYNOL-9 | INACTIVE INGREDIENT | 48Q180SH9T | 2 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 2 | |
| SODIUM PHOSPHATE, DIBASIC | INACTIVE INGREDIENT | GR686LBA74 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- A3739-20 SINGLE SHOT EPIDURAL 20G TUOHY
- Aplicare Povidone-Iodine
- Povidone-Iodine
- IODINE
- CITRIC ACID MONOHYDRATE
- SODIUM PHOSPHATE, DIBASIC
- SODIUM HYDROXIDE
- NONOXYNOL-9
- WATER
- Sodium Chloride
- SODIUM CATION
- CHLORIDE ION
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 51688-6161 | 51688-6161-2 |
| 52380-0001 | 52380-0001-3 |
| 65282-1510 | 65282-1510-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POVIDONE-IODINE | 85H0HZU99M | ACTIM |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| NONOXYNOL-9 | 48Q180SH9T | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | ACTIB |
| WATER | 059QF0KO0R | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBCUTANEOUS | 1 %w/v | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAVENOUS | 200 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / SUBCUTANEOUS | 14 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 2.98 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVENOUS | 78 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAVENOUS | 396 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVENOUS | 78 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION / INTRAMUSCULAR | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | CLOTH / TOPICAL | NA | ||
| SODIUM PHOSPHATE, DIBASIC | SODIUM PHOSPHATE, DIBASIC | GR686LBA74 | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| NONOXYNOL-9 | NONOXYNOL-9 | 48Q180SH9T | SOLUTION / OPHTHALMIC | 0.13 %w/w |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A206171-001 | SODIUM CHLORIDE 0.9% | SODIUM CHLORIDE | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | |
| A206171-002 | SODIUM CHLORIDE 0.9% | SODIUM CHLORIDE | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A206171-001 | AP |
| A206171-002 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-001 | SODIUM CHLORIDE 0.9% | 45MG/5ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-002 | SODIUM CHLORIDE 0.9% | 90MG/10ML (9MG/ML) | SOLUTION / INJECTION | AP | 2017-07-21 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A206171-001 | SODIUM CHLORIDE 0.9% | 9MG/ML | INJECTABLE / INJECTION | AP | 2017-07-21 | 5aa47cf7b7d7… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A206171-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A206171-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A206171-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A206171-002 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-001 | AP | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A206171-002 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-001 | AP | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A206171-002 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-001 | AP | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A206171-002 | AP | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-001 | AP | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A206171-002 | AP | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-001 | AP | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A206171-002 | AP | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-001 | AP | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A206171-002 | AP | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-001 | AP | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A206171-002 | AP | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-001 | AP | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A206171-002 | AP | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-001 | AP | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A206171-002 | AP | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-001 | AP | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A206171-002 | AP | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-001 | AP | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A206171-002 | AP | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-001 | AP | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A206171-002 | AP | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-001 | AP | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A206171-002 | AP | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-001 | AP | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A206171-002 | AP | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A206171-001 | AP | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A206171-001 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A206171-001 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A206171-001 | AP | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A206171-001 | AP | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A206171-001 | AP | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A206171-001 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A206171-001 | AP | 1 | 5aa47cf7b7d7… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sodium Chloride | SODIUM CHLORIDE | Spectra Medical Deviecs, LLC | 7e316d21-d6ad-4976-bd90-268fd7e51361 | 2024-01-12 | Adverse reactions | 65282-1510-1 65282-1510 65282151001 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.


